North America Specialty Pharmaceuticals Market Size, Share and Forecast 2032

North America Specialty Pharmaceuticals Market Overview:

The North America Specialty Pharmaceuticals Market size was valued at USD 67,838.21 MN in 2021 and reached USD 109,086.83 MN in 2025. It is anticipated to reach USD 260,733.67 MN by 2032, growing at a CAGR of 11.03% during the forecast period.

North America Specialty Pharmaceuticals Market Insights

• Market growth is supported by oncology therapy demand, immunology biologic expansion, endocrine specialty drug uptake, rare disease approvals, gene and cell therapy adoption and specialty pharmacy distribution growth.
• Oncology holds a strong position because cancer care increasingly depends on biologics, targeted small-molecule specialty drugs, immunotherapies and gene and cell therapy innovations.
• Biologics remain a leading drug class due to strong use in oncology, immunology, endocrinology, rare diseases and inflammatory disease treatment.
• Hospital Pharmacies remain the leading distribution channel because specialty pharmaceuticals often require specialist diagnosis, prior authorization, cold-chain handling, infusion support and clinical monitoring.

North America Specialty Pharmaceuticals Market Segment Insights

By application

By application, Oncology held the strongest position in 2025 because cancer treatment increasingly uses biologics, targeted therapies, immunotherapies and advanced specialty drugs. Immunology also represents a major application due to biologic use in rheumatoid arthritis, psoriasis, inflammatory bowel disease and other immune-mediated disorders. Endocrinology is expanding rapidly through GLP-1 therapies, diabetes products and obesity-related specialty medicines. Neurology is gaining value due to rare neurologic disorders, multiple sclerosis, migraine, Alzheimer’s disease and neuromuscular therapies. Rare & Orphan Disorders support high-value treatment demand through biologics, gene therapies and precision medicines. Others include infectious disease, hematology, ophthalmology and transplant-related specialty care.

By drug class

By drug class, Biologics held the strongest position in 2025 because many high-value specialty pharmaceuticals are monoclonal antibodies, recombinant proteins, fusion proteins and plasma-derived products. Small-molecule Speciality Drugs remain important in oncology, rare disease, neurology and targeted therapy pathways. Gene & Cell Therapy is gaining momentum as FDA approvals expand for rare genetic diseases, hematologic malignancies and inherited disorders. Pepide Therapeutics are gaining relevance due to endocrine, metabolic and specialty chronic disease applications. Others include oligonucleotide drugs, enzyme replacement therapies, radiopharmaceuticals and advanced immunotherapies. Growth will depend on payer access, clinical outcomes, manufacturing scale and specialty distribution capabilities.

By distribution channel

By distribution channel, Hospital Pharmacies held the strongest position in 2025 because specialty pharmaceuticals often require hospital-led diagnosis, administration and monitoring. Oncology therapies, gene and cell therapies, infusions and rare disease treatments are concentrated in hospital systems and academic medical centers. Retail Pharmacies & Drug Stores remain important for self-administered biologics, endocrine therapies, oral oncology products and chronic specialty medicines. Online Pharmacies are gaining relevance through refill coordination, digital prior authorization, home delivery and patient support programs. Specialty pharmacy models will grow as payers require adherence monitoring, cold-chain control and outcome documentation.

Key Market Drivers

Rising oncology specialty drug demand

Rising oncology specialty drug demand represents a major growth driver for the North America Specialty Pharmaceuticals Market. Cancer care increasingly depends on high-value biologics, targeted small-molecule specialty drugs, immune checkpoint inhibitors, antibody-drug conjugates and cell therapies.

The CDC reported 1,851,238 new cancer cases in the United States in 2022, the latest year for incidence data, reinforcing the large treatment base for oncology specialty medicines. Bristol Myers Squibb reported 2025 worldwide Opdivo revenues of USD 10.0 billion, showing continued commercial strength for immuno-oncology specialty pharmaceuticals. This driver supports Oncology, Biologics, Small-molecule Speciality Drugs, Gene & Cell Therapy and Hospital Pharmacies.

Immunology biologic expansion

Immunology biologic expansion is strengthening specialty pharmaceutical demand across inflammatory bowel disease, psoriasis, rheumatoid arthritis and related immune-mediated disorders. Patients with moderate to severe disease frequently require biologics or advanced specialty therapies after inadequate response to conventional medicines.

AbbVie reported full-year 2025 global immunology portfolio net revenues of USD 30.406 billion, including Skyrizi net revenues of USD 17.562 billion, Rinvoq net revenues of USD 8.304 billion and Humira net revenues of USD 4.540 billion. This commercial momentum supports Immunology, Biologics, Small-molecule Speciality Drugs, Hospital Pharmacies and Retail Pharmacies & Drug Stores.

Endocrinology and GLP-1 specialty therapy growth

Endocrinology and GLP-1 specialty therapy growth is reshaping the market as obesity, diabetes and cardiometabolic treatment demand rises. High-value endocrine therapies require physician oversight, payer management, chronic adherence support and strong pharmacy distribution.

Eli Lilly’s 2025 Form 10-K said Mounjaro and Zepbound accounted for 56% of its total revenues in 2025 and that cardiometabolic health products are expected to remain a significant and growing portion of the company’s business. The driver supports Endocrinology, Pepide Therapeutics, Retail Pharmacies & Drug Stores and Online Pharmacies. Growth will depend on coverage expansion, supply availability, pricing and long-term outcomes data.

Rare disease and gene therapy approvals

Rare disease and gene therapy approvals are accelerating demand for high-value specialty pharmaceuticals. Gene & Cell Therapy products often target small patient populations with high unmet need, creating premium revenue opportunities despite complex manufacturing and distribution.

FDA approved Waskyra in December 2025 as the first cell-based gene therapy for Wiskott-Aldrich syndrome and described it as a patient-specific genetically corrected hematopoietic stem cell therapy. FDA also listed 2025 biological license approvals that included WASKYRA for pediatric and adult patients with Wiskott-Aldrich Syndrome who meet defined transplant-related criteria. This driver supports Rare & Orphan Disorders, Gene & Cell Therapy, Hospital Pharmacies and Specialty Centers.

Key Trends and Opportunities

Specialty pharmacy models expand

Specialty pharmacy models are expanding because complex medicines require prior authorization, adherence monitoring, cold-chain management, refill coordination and patient education. Hospital Pharmacies remain central for infusion and cell therapy, while Retail Pharmacies & Drug Stores and Online Pharmacies are gaining relevance for self-administered biologics, GLP-1 therapies, oral oncology products and chronic specialty medicines. CMS projects retail prescription drug spending to grow at an average annual rate of 5.7% from 2025 to 2034, making it the fastest-growing major national health expenditure category over that period. This trend supports pharmacy-led care coordination and payer-driven specialty distribution models.

Gene and cell therapy pipelines strengthen

Gene and cell therapy pipelines are strengthening as regulators approve more advanced products for rare diseases and severe conditions. FDA’s rare disease drug approvals page tracks recent rare disease approvals, including first-in-class and first-treatment categories, while its 2025 novel drug approval page lists new therapies across oncology, rare disease and specialty indications. These approvals create opportunities for manufacturers, hospitals and payers that can manage complex treatment delivery. Growth will favor institutions with cell processing capacity, reimbursement expertise, patient selection workflows and post-treatment monitoring systems.

Canada rare disease access improves

Canada rare disease access is improving through public policy support, creating opportunities for specialty pharmaceutical manufacturers. The Government of Canada’s National Strategy for Drugs for Rare Diseases aims to improve access to effective rare disease drugs and make them more affordable, with funding available between April 1, 2024 and March 31, 2027. Canada also announced up to CAD 1.5 billion over three years to support the strategy, including up to CAD 1.4 billion for bilateral agreements with provinces and territories. This trend supports Rare & Orphan Disorders, Biologics, Gene & Cell Therapy and hospital-linked specialty access.

Key Market Challenges

High drug cost and payer pressure

High drug cost and payer pressure remain major challenges for the North America Specialty Pharmaceuticals Market. Specialty drugs often carry premium prices because they require complex manufacturing, clinical evidence generation, patient support, temperature-controlled logistics and targeted prescribing. Payers frequently use prior authorization, step therapy, formulary exclusions and specialty pharmacy mandates to control spending. This can slow adoption in Oncology, Immunology, Endocrinology and Rare & Orphan Disorders. Manufacturers must demonstrate clear clinical value, real-world outcomes and budget impact evidence to support reimbursement.

Manufacturing and supply chain complexity

Manufacturing and supply chain complexity can restrict product availability and increase market risk. Biologics, Gene & Cell Therapy products and selected specialty drugs require advanced production platforms, batch controls, sterile processing, cold-chain logistics and regulatory oversight. Cell therapies add chain-of-identity requirements, specialized site certification and patient-specific scheduling. Supply disruptions can delay therapy initiation and affect treatment continuity. Companies need robust quality systems, redundant supply capacity, specialty distribution partners and strong product traceability to support growth.

Biosimilar and generic competition

Biosimilar and generic competition creates pricing pressure in mature specialty categories. Biologics in immunology and oncology face growing biosimilar substitution, payer tendering and rebate competition. Health Canada notes that biosimilar biologic drugs must meet rigorous authorization standards for quality, safety and efficacy, although authorization does not declare equivalence to the reference biologic. This environment can improve access but reduce originator revenue. Companies must defend share through new indications, lifecycle management, patient support, device improvements and clinical differentiation.

Regional Analysis

United States

The United States leads the North America Specialty Pharmaceuticals Market due to its large oncology burden, advanced biologics use, strong specialty pharmacy infrastructure, high payer involvement and rapid adoption of innovative therapies. Oncology, Immunology, Endocrinology and Rare & Orphan Disorders drive demand across Biologics, Small-molecule Speciality Drugs and Gene & Cell Therapy. FDA approvals for rare disease therapies and gene therapies support high-value market expansion, while CMS drug spending projections indicate continued prescription drug market growth. Hospital Pharmacies and specialty pharmacy networks will remain central to distribution through 2032.

Canada

Canada represents a mature specialty pharmaceuticals market supported by universal health care systems, provincial reimbursement frameworks, biologic regulation and rare disease policy initiatives. The National Strategy for Drugs for Rare Diseases supports access and affordability, while Health Canada’s biosimilar framework helps shape biologic competition and payer strategy. Oncology, Immunology, Rare & Orphan Disorders and Endocrinology remain key demand areas. Hospital Pharmacies support high-complexity therapies, while Retail Pharmacies & Drug Stores support chronic specialty drug dispensing. Growth will depend on price negotiations, provincial formularies, pan-Canadian Pharmaceutical Alliance outcomes and access agreements.

Mexico

Mexico is an emerging growth market within North America due to expanding private hospital capacity, rising demand for oncology and immunology therapies and increasing interest in advanced specialty drugs. Access remains more uneven than in the United States and Canada due to affordability, reimbursement variation and specialty care concentration in large urban centers. Hospital Pharmacies dominate high-cost specialty therapy access, while Retail Pharmacies & Drug Stores support selected endocrine, immunology and oral specialty medicines. Growth will depend on public procurement, private insurance coverage, multinational product launches, physician training and cold-chain distribution quality.

Report Attribute Details

North America Specialty Pharmaceuticals Market segmentations

By Application

• Oncology
• Immunology
• Endocrinology
• Neurology
• Rare & Orphan Disorders
• Others

By Drug Class

• Biologics
• Small-molecule Speciality Drugs
• Gene & Cell Therapy
• Pepide Therapeutics
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

Key Players

• AbbVie
• Amgen
• AstraZeneca
• Bayer AG
• Biogen
• BioMarin
•  Boehringer Ingelheim
• Bristol Myers Squibb
• CSL Behring
• Eli Lilly
• Gilead Sciences
• GSK plc

Recent Developments

• In February 2026, AbbVie reported full-year 2025 global immunology portfolio net revenues of USD 30.406 billion, supported by Skyrizi, Rinvoq and Humira.
• In February 2026, Eli Lilly reported that fourth-quarter 2025 revenue increased 43% to USD 19.3 billion, driven by volume growth from Mounjaro and Zepbound.
• In February 2026, Gilead Sciences reported full-year 2025 HIV product sales of USD 20.8 billion, up 6% from 2024, driven primarily by higher demand for HIV treatment and prevention.
• In December 2025, FDA approved Waskyra, the first cell-based gene therapy for Wiskott-Aldrich syndrome, strengthening the U.S. rare disease gene therapy landscape.

Report Coverage

The research report offers an in-depth analysis based on application, drug class, distribution channel and geography. It details leading market players, providing an overview of their business positioning, specialty drug portfolios, biologics exposure, oncology products, immunology platforms, endocrine therapies, rare disease assets, gene and cell therapy strategies and distribution relevance in the North America Specialty Pharmaceuticals Market. The report includes insights into the competitive environment, market trends, growth drivers, restraints and opportunities. It also examines oncology demand, immunology biologic expansion, endocrine specialty therapy growth, rare disease approvals, specialty pharmacy models, payer controls, biosimilar competition and hospital pharmacy infrastructure as major factors shaping market development. The report assesses the impact of high therapy cost, reimbursement pressure, supply chain complexity, manufacturing risk, cold-chain requirements and payer management on market growth. It provides strategic recommendations for pharmaceutical companies, hospital systems, specialty pharmacies, retail pharmacy networks, online pharmacies, payers, distributors, investors and new entrants seeking to navigate North America’s specialty pharmaceuticals ecosystem.

Future Outlook

• Demand for specialty pharmaceuticals will continue to rise as oncology, immunology, endocrinology, neurology and rare disease treatment expand across North America.
• Oncology will remain a leading application due to continued use of biologics, targeted small-molecule specialty drugs and advanced therapies.
• Immunology will grow through biologics and advanced specialty drugs for inflammatory and autoimmune diseases.
• Endocrinology will expand as GLP-1 therapies, diabetes products and obesity-related specialty drugs gain wider use.
• Rare & Orphan Disorders will gain share as gene therapy, enzyme replacement and targeted rare disease products expand.
• Biologics will remain the leading drug class due to broad adoption across cancer, immunology and rare disease care.
• Gene & Cell Therapy will grow as FDA approvals and hospital treatment infrastructure expand.
• Hospital Pharmacies will remain the leading channel for complex therapies, infusions, oncology drugs and gene therapies.
• Online Pharmacies will gain relevance through refill coordination, digital authorization and chronic specialty drug delivery.
• Competition will increase as companies compete on clinical differentiation, access programs, payer evidence, biosimilar defense, specialty distribution and product innovation.